连续性高容量肾脏替代治疗对胰腺炎合并急性肾衰竭患者血清中PCT、TNF-α、IL-6和IL-8表达的影响

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence of high-volume continuous renal replacement therapy (HV-CRRT)on procalcitonin(PCT),tumor necrosis factor-α (TNF-α),IL-6,and IL-8 in acute pancreatitis complicated with acute renal failure.Methods Eighty-six patients with acute pancreatitis complicated with acute renal failure who treated by continuous veno-venous hemofiltration (CVVH)in our hospital from September 2014 to September 2017 were selected as the subjects,and divided into two groups by different ultrafiltration rate,with 43 cases in each group.The patients in the control group treated by the normal capacity model with a ultrafiltration rate was 20 ml/(kg·h),and the observation group treated by the HV-CVVH model with a ultrafiltration rate was 35 ml/(kg·h).The levels of PCT,TNF-α,IL-6,and IL-8 in serum were measured by ELISA before and at 2,6,12 h after treatment,and 12 h after CVVH.Results The serum PCT,TNF-α,IL-6 and IL-8 levels in the two groups were decreased at 2 h after treatment.The lowest levels appeared at 6 h after treatment,and the PCT,TNF-α,IL-6 and IL-8 levels in the observation group were lower than those in the control group after treatment(P＜0.05).ConclusionHV-CRRT can more effectively remove various inflammatory factors and reduce the levels of serum PCT for the treatment of pancreatitis complicated by acute renal failure.Additionally,replacement of the blood filter at appropriate time-points can improve the treatment effect．

Key words： Continuous renal replacement therapy High capacity hemofiltration Procalcitonin Pancreatitis Acute renal failure Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I3/44

[1]	杨婷，吴建维，汤红玲，等.埃索美拉唑联合生长抑素治疗重症胰腺炎的效果[J].中国当代医药，2018，25（23）：166-168.
[2]	张太平，杨刚，赵玉沛.重症急性胰腺炎诊治进展[J].中华肝脏外科手术学电子杂志，2017，6（1）：1-5.
[3]	Lakhotia M，Pahadiya HR，Kumar H，et al.Acute pancreatitis，ascites，and acute renal failure in Plasmodium vivax malaria infection，a rare complication[J].Trop Parasitol，2015，5（2）：120-122.
[4]	王逸平，刘向新，崔晓莉，等.重症急性胰腺炎并发急性肾损伤临床特征及危险因素分析[J].交通医学，2017，31（5）：473-476.
[5]	Sutherland SM，Goldstein SL，Alexander SR.The prospective pediatric continuous renal replacement therapy（ppCRRT）registry：a critical appraisal[J].Pediatr Nephrol，2014，29（11）：2069-2076.
[6]	杨荣萍，廖旭，胡元佳，等.新亚特兰大分类下生化指标预测急性胰腺炎严重度的价值[J].胃肠病学和肝病学杂志，2016，25（8）：899-902.
[7]	刘琴.持续性与间歇性血液净化治疗重症急性胰腺炎合并急性肾衰竭效果对比[J].深圳中西医结合杂志，2017，27（1）：132-133.
[8]	吴燕生，郁毅刚，陈桂喜.连续肾脏替代疗法治疗脓毒症效果及炎症反应、血流动力学的变化[J].解放军医药杂志，2017，29（11）：42-46.
[9]	Clark E，Molnar AO，Joannes-Boyau O，et al.High-volume hemofiltration for septic acute kidney injury：a systematic review and meta-analysis[J].Crit Care，2014，18（1）：R7.
[10]	徐燕，张健，殷洪明.降钙素原临床应用的研究进展[J].国际检验医学杂志，2016，37（24）：3463-3464.
[11]	王国荣.血清降钙素原联合C-反应蛋白在脓毒症诊断中的应用价值分析[J].中国当代医药，2018，25（9）：126-128.
[12]	王建林.降钙素原对全身炎症反应综合征患者病情预后的判断价值分析[J].中外医疗，2017，36（32）：24-25.
[13]	颜瑶，郭晓芳，施青山，等.血清降钙素原在细菌性脓毒症合并急性肾损伤患者的诊断价值[J].中国中西医结合肾病杂志，2016，17（3）：243-246.
[14]	张浩，潘达，朱丽明，等.钙调蛋白及肿瘤坏死因子-α对介导急性坏死性胰腺炎心肌损害的作用[J].世界华人消化杂志，2015，23（26）：4162-4166.
[15]	彭艳，文刚，彭雪刚，等.重症胰腺炎患者血淀粉酶、TNF-α、IL-1β和PCT在CRRT治疗后的变化和意义[J].标记免疫分析与临床，2017，24（9）：1011-1014.
[16]	程海燕，陈先国，徐元宏.白细胞介素6与自身免疫性疾病关系的研究进展[J].细胞与分子免疫学杂志，2016，32（9）：1285-1287.
[17]	王海芳，王艳，高淑霞，等.连续性静-静脉血液滤过技术对全身性炎症反应综合征伴肾功能衰竭患者血液动力学的影响[J].海南医学，2016，27（20）：3386-3388.